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Abstract
Background: Parasite-based diagnosis of malaria by microscopy requires laboratory skills that are generally unavailable
at peripheral health facilities. Rapid diagnostic tests (RDTs) require less expertise, but accuracy under operational
conditions has not been fully evaluated in Uganda. There are also concerns about RDTs that use the antigen histidine-
rich protein 2 (HRP2) to detect Plasmodium falciparum, because this antigen can persist after effective treatment, giving
false positive test results in the absence of infection. An assessment of the accuracy of Malaria Pf™ immuno-
chromatographic test (ICT) and description of persistent antigenicity of HRP2 RDTs was undertaken in a hyperendemic
area of Uganda.
Methods: Using a cross-sectional design, a total of 357 febrile patients of all ages were tested using ICT, and compared
to microscopy as the gold standard reference. Two independent RDT readings were used to assess accuracy and inter-
observer reliability. With a longitudinal design to describe persistent antigenicity of ICT and Paracheck, 224 children aged
6–59 months were followed up at 7-day intervals until the HRP2 antigens where undetectable by the RDTs.
Results: Of the 357 patients tested during the cross-sectional component, 40% (139) had positive blood smears for
asexual forms of P. falciparum. ICT had an overall sensitivity of 98%, a specificity of 72%, a negative predictive value (NPV)
of 98% and a positive predictive value (PPV) of 69%. ICT showed a high inter-observer reliability under operational
conditions, with 95% of readings having assigned the same results (kappa statistics 0.921, p < 0.001).
In children followed up after successful antimalaria treatment, the mean duration of persistent antigenicity was 32 days,
and this duration varied significantly depending on pre-treatment parasitaemia. In patients with parasite density >50,000/
μl, the mean duration of persistent antigenicity was 37 days compared to 26 days for parasitaemia less than 1,000/μl (log
rank 21.9, p < 0.001).
Conclusion: ICT is an accurate and appropriate test for operational use as a diagnostic tool where microscopy is
unavailable. However, persistent antigenicity reduces the accuracy of this and other HRP2-based RDTs. The low
specificity continues to be of concern, especially in children below five years of age. These pose limitations that need
consideration, such as their use for diagnosis of patients returning with symptoms within two to four weeks of treatment.
Good clinical skills are essential to interpret test results.
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Background
Prompt and accurate diagnosis of malaria is the key to
effective case management and a major component of
Uganda's malaria control strategy. Clinical diagnosis is
the least expensive and most widely practised method and
the one generally used for self treatment. However, the
overlapping of malaria symptoms with other tropical dis-
eases impairs its specificity and can promote the indis-
criminate use of anti-malarials and compromise quality of
care for patients with non-malarial fevers in endemic
areas [1]. Therefore the accuracy of malaria diagnosis can
be greatly enhanced by combining clinical and parasite-
based findings.
Conventional light microscopy is the "gold standard" for
routine parasite-based diagnosis because it is sensitive,
inexpensive to perform, can differentiate malaria species
and quantify parasite load. Microscopy requires well-
trained technicians, a microscope in good working order
and a well-functioning quality assurance system. The chal-
lenges for governments to ensure that such prerequisites
are in place mean that microscopy is unavailable at many
peripheral health facilities in resource limited settings,
where most cases are managed in the public health sector.
Rapid diagnostic tests (RDTs) require less expertise to be
conducted correctly, and non-specialized staff can be
quickly trained to use them. Malaria diagnostic accuracy
may be strengthened by the use of RDTs where micros-
copy is not available or feasible to maintain.
Uganda changed its malaria drug policy in 2004 from
chloroquine plus sulphadoxine-pyremethamine (CQ+SP)
to artemisinin-based combination therapy (ACT) using
Coartem™ (artemether-lumefantrine) as the first-line
treatment. ACT is a more expensive treatment than the
previous drug combination of CQ+SP, and the Ministry of
Health (MoH) is thus keen to shift malaria diagnosis to
become parasite-based rather than clinical. This is to
ensure that only confirmed cases of malaria receive anti-
malarials and differential diagnosis is utilized to identify
the cause of fever in cases giving a negative result for
malaria. In this way, the quality of care of fever cases will
be greatly improved and the wastage of anti-malarials will
be minimized.
A review of studies evaluating diagnostic tools for malaria
found very high accuracy and reliability of RDTs [2]. The
tests are cost effective and can lead to cost saving when
used instead of clinical diagnosis and treatment [3].
Malaria antigens currently targeted by RDTs are histidine
rich protein 2 (HRP2), which is unique to Plasmodium fal-
ciparum, Plasmodium lactate dehydrogenase (pLDH), and
Plasmodium aldolase. The current policy guideline in
Uganda recommends use of HRP2, due to the very high
proportion of P. falciparum infections [4].
HRP2-based RDTs are very sensitive in detecting P. falci-
parum infections, are heat stable[5] and generally cost less
than many of the other types of RDTs [6]. However, per-
sistent antigenicity in blood after treatment can reduce the
specificity of these RDTs in previously infected individu-
als, especially in highly endemic areas. In these areas, the
duration of persistent HRP2 varies widely and can be four
weeks or longer [7-9]. Low specificity and false positive
RDTs results leads to misuse of anti-malarials, and conse-
quently increased drug presure and indirectly contributes
to drug resistance in such cirmustances.
Currently, there is limited information on the accuracy of
Malaria Pf™ ICT (ICT) marketed by ICT Diagnostics,
South Africa. The data available [3,7,10-16] is based on
three other RDTs that have all evolved from the one orig-
inal product. Although ICT is very similar to these three
RDTs, it has a different format and nitrocellulose strip and
is manufactured at a different site – factors recognized to
have a potential influence on the test's sensitivity and spe-
cificity. In addition, ICT detects P. falciparum only, unlike
previously evaluated RDTs that detect all four human
malaria species. There have been a number of other stud-
ies on malaria RDTs done in Uganda [17-21].
This study assesses the operational accuracy and ease of
use (inter-observer and intra-test reliability) of ICT in a
district hospital setting. It also describes persistent HRP2
antigenicity of both ICT and Paracheck Pf (another HRP2-
based RDT) in children aged 6–59 months treated for
malaria in a hyperendemic setting in Uganda.
Methods
Study site
The study was conducted as two independent serial com-
ponents. A cross-sectional assessment was performed to
determine the accuracy of ICT for P. falciparum infection
using microscopy as the gold standard. In addition, a lon-
gitudinal design was used to describe persistent antigenic-
ity using two HRP2 tests (ICT and Paracheck). Both
components were undertaken in Soroti Regional Referral
Hospital, Uganda. Soroti town is 347 kilometres north of
the capital Kampala and is in an area of hyperendemic
malaria with a parasite prevalence of 85% in children
below nine years of age [4]. The out-patient department
(OPD) handles, on average, 18,000 suspected malaria
cases per year, of which 50% have blood smears per-
formed; the majority of these (60%) are positive for
malaria (MoH Uganda, unpublished data). The study pro-
tocol was approved by the Uganda National Council of
Science and Technology.
Study participants
For both study components, consecutive patients present-
ing to the OPD were screened for symptoms/history sug-Malaria Journal 2008, 7:221 http://www.malariajournal.com/content/7/1/221
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gestive of malaria and evaluated for eligibility into the
study. During the cross-sectional component, patients
who fulfilled the following criteria were enrolled: 1) aged
six months and above; 2) history of fever in the last 24
hours or axillary temperature ≥ 37.5°C; 3) no evidence of
a concomitant febrile illness; 4) provision of informed
consent; 5) no danger signs or evidence of severe malaria.
For the longitudinal component, only children aged 6–59
months and residing within seven kilometres from the
hospital were recruited. The additional inclusion criteria
were as follows: 1) Plasmodium falciparum monoinfection
on blood smear; 2) positive RDT test results; 3) no evi-
dence of a concomitant febrile illness; 4) no danger signs
or evidence of severe malaria; 5) provision of informed
consent including extended follow-up; and 6) negative
blood smear for asexual-stage peripheral parasitaemia on
day-3 after anti-malarial therapy.
Study procedures
Cross-sectional component procedures
At screening, patients or guardians were asked about prior
anti-malarial use and presence of common symptoms.
Weight and axillary temperature were measured and a
physical examination performed and patients that pro-
vided consent were referred to the laboratory for investi-
gation.
In the laboratory, blood was obtained by finger prick for
thick and thin blood smears, for RDT and a drop was
taken on a filter paper for possible future molecular anal-
ysis.
Blood smears were stained with 10% Giemsa for 30 min-
utes. Thick smears were examined for parasites including
gametocytes and parasite densities were determined by
counting the number of asexual parasites per 200 white
blood cells (WBC), or per 500 WBC if the parasite count
was less than 10 parasites per 200 WBC, assuming a WBC
count of 8,000/μl. A slide was considered negative if no
parasites were seen after reviewing 100 high power fields.
Thin smears were read to determine the Plasmodium spe-
cies. Patients were managed based on microscopy results
and national treatment guidelines. Medication was dis-
pensed at a general OPD pharmacy unsupervised by the
study team.
A RDT result was interpreted as positive when both the
test line and control line showed pink, negative when
only the control line showed pink or invalid when the
control line did not appear regardless of the test line. Two
independent readings were graded based on visual assess-
ment as "strong" or "faint positive" for reactive tests and
"negative" for non-reactive ones. A test result was graded
"strong" if the test line was as intense as the control line
and a "faint" result was a line that could only be seen in
good light. The reason for this distinction on the positive
line intensity is that a strong result is very clear, but faint
positive lines can easily be missed in situations where the
lighting is poor or the operator has poor eyesight. Grading
was also used to determine the source of variability in
results reported by two independent readers. Any invalid
RDT tests were not repeated.
Longitudinal component procedures
During the longitudinal component of the study, patients
were evaluated simultaneously using Paracheck and ICT
RDTs at screening and on every follow-up day. Only
patients with a negative day-3 smear were enrolled for the
longitudinal component. Enrolled patients were asked to
return for follow-up on day-7 and every subsequent seven
days or any other day that they felt ill. Follow-up evalua-
tion consisted of taking finger prick blood for RDT tests
and blood smears. Enrolled patients with complaints were
also clinically evaluated and managed. The follow-up
period ended when an outcome was determined as either
smear-positive or RDT-negative. Patients with positive
smears were referred to the clinician for evaluation and
treatment.
Operational quality control
Local hospital staff were involved in the day-to-day con-
duct of the study. Both laboratory and clinical teams were
trained to perform the RDT. The training was followed
with a pilot study of about 20 patients to ensure that all
study procedures were clearly followed and that the study
did not cause any unnecessary interference to the normal
functioning of the clinics and the laboratory. Laboratory
technologists were assigned work according to hospital
duty register. All study slides were read by first and second
microscopists who were blinded to each others' results.
The same second microscopist was maintained through-
out the longitudinal component to ensure consistency.
Reading were considered discordant for the following sce-
narios: 1) positive/negative discordance for asexual stages;
2) species discordance; 3) asexual discordance of more
than 50% difference between the parasitaemia; 4) posi-
tive/negative discordance for gametocytes. A third, exter-
nal microscopist, unaware of the first two results, resolved
any discordant results and read a further random 10% for
external quality control purposes. Similar to microscopy,
RDT cassettes were labelled and read by two laboratory
technologists independently 15 minutes after adding
buffer. Temperature and humidity for the storage condi-
tions for RDTs during study period were monitored using
Tinytag™ Data Loggers http://www.tinytag.info with an
alarm set at 37°C.Malaria Journal 2008, 7:221 http://www.malariajournal.com/content/7/1/221
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Study outcome measures
The outcome measures were RDT and microscopy results
for the cross-sectional component. During the longitudi-
nal component, the possible outcomes at each follow-up
evaluation were; 1) positive RDT and negative smear
interpreted as persistent antigenicity; 2) both RDTs and
smear negative interpreted as cleared antigen; and 3) pos-
itive RDT and positive smear interpreted as a recurrence of
asexual parasites (possible recrudescence or re-infection).
Patients with persistent antigenicity at any time point
were given a 7-day follow-up appointment. Patients were
excluded from further follow-up if they withdrew consent
or both RDT readings were invalid or not interpretable.
Sample size estimation
To determine accuracy of ICT, sample size was calculated
considering a sensitivity of 90% and a prevalence of
malaria in the study population of 50% (among children
under 10 years). Using the nomogram by Carley et al [22],
at a precision of 5% and an alpha error of 0.05, a sample
population of 300 subjects plus an additional 10% to
allow for invalid and unclear results was estimated.
For the longitudinal component, to describe and deter-
mine predictors of persistent antigenicity, a sample of 224
participants that completed follow-up showed >80%
power of detecting a difference between low parasite den-
sity (less than 1,000/μl), and high (>50,000/μl) day-zero
parasitaemia.
Statistical methods
Data were entered and verified using EpiData 3.01http://
www.epidata.dk and analysed using SPSS version 12.0
http://www.spss.com. Overall agreement, as a measure of
reliability of RDT readings was calculated using a kappa
statistics. Using microscopy as the reference, sensitivity of
the RDT was measured as the proportion of RDT positives
over the total positives determined by microscopy and
specificity as proportion of RDT negatives over the total
negatives determined by microscopy. The positive predic-
tive value (PPV) is the number of RDT true positives
divided by the number all RDT positive test results (true
positive plus false positives). The negative predictive value
(NPV) is the number of RDT true negatives divided by the
number all RDT negative test results (true negatives plus
false negatives).
Duration of persistent antigenicity was measured as time
in days, when RDT remains positive after treatment and
the blood slide remains negative. Data from patients with
recurrent parasitaemia were included in the analysis of
persistent antigenicity until the day the microscopy smear
became positive and an outcome measure of the previous
time-points assigned. Inter observer reliability of ICT and
intra-test reliability of ICT and Paracheck were calculated
using Kappa statistics. For analysis purposes, day-zero par-
asite density was categorized into three groups; <1,000/μl,
1,000–50,000, and > 50,000/μl. The mean duration was
determined for persistent antigenicity (survival analysis
techniques) and compared equality of survival distribu-
tion for categorized day-zero parasite density using log
rank test statistics.
Results
Study participants
The study was conducted between October 2006 and Sep-
tember 2007 in Soroti Hospital Out-Patients Department
(OPD) in two components. During the cross sectional
component, 364 patients were recruited into the study,
but seven patients were excluded from this analysis
because of unreadable blood smears. Of the 357 patients
evaluated, the median (IQR) age was 11 (1–28) years,
46% were under the age of five, and 60% female. A total
of 139 (39%) had positive blood smears for asexual forms
of P. falciparum, predominately in the children under five
years, where 102 (73%) were positive (Table 1).
During the longitudinal component to describe persistent
antigenicity, a total of 310 febrile children with P. falci-
parum monoinfection were screened with both ICT and
Paracheck RDTs on day-zero. On day-3, participants were
evaluated to determine anti-malarial treatment response.
Of the 310 patients screened on day-zero, 51(16.4%)
were not enrolled in the follow-up component due to the
following reasons: sixteen still had asexual parasitaemia
(early treatment failures); three children with negative
smears on day-zero had been included in violation of the
protocol, while 32 children who missed day-3 evaluation
were excluded because anti-malarial treatment response
could not be determined in time. Out of the 259 children
successfully enrolled for follow-up after day-3 evaluation,
three patients withdrew consent citing unwillingness to
continue with a hospital based follow-up and thirty-two
others failed to honour appointments during the course
of follow-up (Figure 1).
Operational accuracy of ICT
The ICT had a sensitivity of 98% (95% CI: 94–99) and
specificity of 72% (95% CI: 65–77). The specificity of ICT
was significantly lower in the <5 years at 54% (95% CI:
41–67) compared to 78% (95% CI: 71–85) in the older
age group. Overall, ICT test had a NPV of 98% (95% CI:
95–100) and PPV of 69% (95% CI: 62–75). The 78%
(95% CI 58–70) PPV in the under fives is significantly
higher than 51% (95% CI 39–64) in the above fives
(Table 2). Of the 198 positives ICT test, 62(31%) were
false positive. There were 159 negative ICT results of
which three were false negatives. Two out of the three false
negative results had a low parasite density of 32 and 440/Malaria Journal 2008, 7:221 http://www.malariajournal.com/content/7/1/221
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μl, while the third false negative RDT had a high parasite
density of 70,400/μl.
Reliability of HRP2 tests
For the cross-sectional component of the study, the results
of the first and second ICT readings were highly compara-
ble with 336/354 (95%) concordant reading (kappa statis-
tics 0.921, p < 0.001), showing a very high operational
test reliability.
During the longitudinal component of the study, all tests
were performed using ICT and Paracheck RDTs. Results
where graded as "strong" positive, "faint" positive and
negative. Comparing ICT and Paracheck paired tests done
for the same patient during the follow-up component
showed 1488/1559(95%) concordance between the two
RDT results. The major difference between the two HRP2
tests was in terms of line intensity as "strong" versus
'faint" positives. There were 17 discordant pairs, for which
ICT showed 14 as negative while Paracheck showed "faint
positive". Two "faint positive" ICT tests were negative on
Paracheck. Only one negative ICT showed "strong posi-
tive" with Paracheck. Overall, there were eight invalid ICT
tests (Table 3). When all strong and faint positives where
grouped as positives, diagnosis interpretations for both
test results showed 1542/1559 (99%) concordance. The
results showed very high intra-test reliability (kappa statis-
tics = 0.98, p < 0.001) and further analysis below is pre-
sented simply as HRP2 results and does not distinguish
between the two RDTs.
Persistent HRP2 antigenicity
For all the 310 children screened on day-zero, there was
no significant difference at baseline of gender, age, tem-
perature, parasite density, presence of gametocytes or
recent anti-malarial use between those who completed
follow-up and the ones that did not (Table 3). At the end
of the follow-up period, 224/259 (86.4%) children had
been assigned an outcome for persistent antigenicity (Fig-
ure 1).
Of these, 162 (72%) were followed up until the antigenic-
ity was no longer detectable while 62 (28%) had recurrent
peripheral parasitaemia detected by microscopy during
the course of the follow-up time at which point they were
no longer followed-up. Persistent antigenicity was docu-
mented in 98% of the cases on day-7 and this decreased
to 14% by day-35 (Table 4). The overall mean duration of
persistent antigenicity was 32 days (95% CI: 31–34) and
median of 35 (95% CI: 33–37) days. Pre-treatment para-
site density predicted duration of antigenicity after adjust-
ing for age, temperature and prior anti-malarial use. In
patients with pre-treatment parasite density >50,000/μl,
the mean duration of persistent antigenicity was 37 days
compared to 26 days for parasitaemia less than 1,000/μl
(log rank 21.9, p < 0.001)(Figure 2). The results remained
statistically significant when parasite densities were reclas-
Table 1: Baseline characterizes of participants in the HRP2 RDT evaluation study, Soroti Hospital, Uganda, October 2006 and 
September 2007
Cross-sectional component Longitudinal component
Characteristics Microscopy result (n = 357) Follow-up events (= 310)
Positive (n = 139) Negatives (n = 218) Completed (n = 224) Lost (n = 86)
Female, n(%) 64(40%) 145(65%) 122(55%) 46(54)
Age in years, median (IQR) 1.0(0.8–6.0) 23(3.0–34.0) 1.3(0.8–2.0) 1.2(0.7–1.6)
Children less than 5 years, n(%) 102 (73) 61(28) All All
Temperature °C, mean (SD) 38.0(1.3) 36.8(0.9) 38.0 (1.2) 37.8 (1.2)
Anti-malarial use in previous 2 weeks 54(39%) 103(65%) 156(70) 58(67)
Parasite density/μl, geometric mean 60,074 - 31,460 29,195
Gametocytes on day-zero, n (%) 7(5%) - 9(4%) 4(5%)
Weight in kilograms, mean(SD) - - 10.0(2.7) 9.4(2.4)
IQC, interquartile range: SD, standard deviationMalaria Journal 2008, 7:221 http://www.malariajournal.com/content/7/1/221
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Longitudinal component patient profile Figure 1
Longitudinal component patient profile. Longitudinal component patient profile showing screened patients, smear and 
rapid diagnostic test (RDT) results and the number that were followed up. At the beginning of the longitudinal component to 
evaluate persistent antigenicity of HRP2 RDTs, 259 children were enrolled on day-3. 224 remained in the study until an out-
come was determined (at the end of the follow up when either the RDTs were negative or smear was positive due to recur-
rent parasitaemia).
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sified as well when patients lost to follow-up were
included.
Discussion
The study evaluated the performance of the ICT rapid
diagnostic test relative to microscopy in an operational
setting. The results of the study demonstrate that ICT test
is an accurate and reliable method of diagnosing P. falci-
parum malaria in the context of microscopy. The very high
sensitivity of 98% implies that the majority of malaria
case among this population would be accurately diag-
nosed, giving the clinician the confidence that true cases
of malaria are rarely missed. Most false negatives are
linked to low parasitaemias which are unlikely to be the
primary cause of illness. There were three false negatives
results, two with parasite density <1,000/μl and one with
parasite density > 5,000/μl. The last result where the para-
site density was high, has been described by other investi-
gators as a very rare event which may be caused by a
prozone effect or by the presence of a mutation or dele-
tion within the HRP2 gene [23]. Two studies have
reported cases of false negatives at very high parasitaemia
with both a pLDH-based test and a HRP2 test with
repeated testing [24,25], but again in very low numbers –
1 case out of 58 and 2 cases out of 196 patients respec-
tively.
Related to the high sensitivity, IC T demonstrated a very
high NPV in this study population that allows a clinician
to confidently diagnose negative-test patients as non
malaria patients and look for other causes of fevers. The
averted non-malarial treatments would lead to cost saving
in the health sector and improved quality of care [3,26].
The results showed a relatively low specificity especially in
the under fives where it was 54%. Having a lower specifi-
city, which leads to over diagnosis and treatment, was
considered to result into less serious consequences than a
low sensitivity in the context of clinical diagnosis. It is
worth noting however, that the PPV in the under 5s was
78% which might be perceived as surprisingly high with
such a low specificity and is linked to the high prevalence
of malaria in this population. It is very likely that the low
specificity has resulted from persistent antigenicity in
patients who had recently been successfully treated for
malaria.
ICT was found to be a reliable test with a high inter-reader
and intra-test reliability Only 8 (2%) discordant records
were assigned different interpretations as "faint positives"
versus negative results. There was a high level of result
concordance between ICT and Paracheck tests during lon-
gitudinal component. The two HRP2 tests were of compa-
rable accuracy and performance in an operational setting.
This implies that given minimum training, it is feasible for
field workers to interpret and report consistent results.
The study also described the duration of ICT false positiv-
ity due to persistent antigenicity and its relationship to
pre-treatment P. falciparum parasite density in Ugandan
children. Overall, persistence of HRP2 antigenicity was
detectable in the majority of children at three weeks fol-
lowing successful treatment. The mean duration of 32
days is particularly worrying because HRP2 persistent
Table 2: Accuracy of malaria P.f. ™ ICT rapid diagnostic test for the detection of Plasmodium falciparum infection in 357 patients 
attending out-patient clinic in Soroti Hospital, Uganda
Accuracy measure Overall (n = 357) < 5 years (n = 163) ≥ 5 years (n = 194)
% (95% CI) % (95% CI) % (95% CI)
Sensitivity 98 (94–99) 98 (93–100) 97(86–100)
Specificity 72 (65–77) 54 (41–67) 78 (71–85)
Positive predictive value 69 (62–75) 78 (58–70) 51 (39–64)
Negative predictive value 98 (95–100) 94 (81–99) 99 (96–100)
ICT true positives, n(% pos) 136(69%) 36(51%) 100(78)
ICT true negatives, n(% neg) 156(98%) 123(99%) 33(94%)
Table 3: Comparison of two HRP2 rapid diagnostic tests in a longitudinal follow-up of 310 children with P. falciparum monoinfection in 
Soroti Hospital, Uganda
RDT type Paracheck
ICT Strong Positive Faint Positive Negative Invalid
Strong Positive 904 20 0 0
Faint Positive 23 424 2 2
Negative 1 14 159 0
Invalid 3 4 0 1Malaria Journal 2008, 7:221 http://www.malariajournal.com/content/7/1/221
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antigenicity reduces the accuracy of the RDT test. This is
more of concern in hyperendemic areas, where frequent
malaria infections mean that children are likely to have
the antigen in their blood even if their fever is not caused
by malaria. There is a danger of over-diagnosis of malaria
based on the interpretation of HRP2 test results. Misdiag-
nosis results in poor quality of care as the appropriate ill-
ness may not be addressed in time. It may also result in
misuse of anti-malarials, poor resource allocation and, cli-
nicians doubting the efficacy of the medicine used. Clini-
cal skills in taking history and eliciting signs are essential
when interpreting RDT results in an effort limit misuse of
anti-malarials. Misuse of anti-malarial contributes to drug
pressure and spreading of drug resistant P. falciparum [27],
resulting in increased malaria-specific mortality, espe-
cially in children[28].
Previous studies from Asian countries have also reported
persistent antigenicity after malaria clinical cure and the
levels reported have varied widely, with ranges of 29–65%
on day-7 [7,8,29-31]. In this study, longer durations of
persistent antigenicity were reported and were shown to
be associated with high parasite density. In general para-
site densities are significantly higher in Africa than in Asia
and may explain why similar studies in Asia have not
found such a high level of prolonged false positivity.
These results show that the high parasitaemia is directly
proportional to persistent antigenicity and support what
Swarthout and others found in the DR Congo, another
hyperendemic region in Africa[8].
The causes of persistent antigenicity after malaria therapy
are still debatable. Previous studies have listed causes of
persistent antigenicity as parasite density levels below
detection threshold for microscopy[32], delayed clearance
of circulating antigens and, presence of gametocytes that
also produce the antigen [9]. The most plausible explana-
tion in this study is the high pre-treatment parasitaemia.
Patients with high parasite densities have large amounts
of HRP2 antigen secreted in proportion to the parasite
numbers [33] and to their stage of development [34]. Ele-
vated concentrations of HRP2 evidently take longer to
eliminate [29] which seems to be supported by the find-
ings of this study. The observed 28% recurrence of parasi-
taemia during follow-up may be a reflection of resistant
parasites that persisted as sub-patent parasitaemia (<50
parasites/μl) or new infections. This raises the question of
whether the positive results with the RDTs were actually
false positives or the RDT was correctly detecting these
sub-patent infections[32]. However, a recent study in
Uganda found 29% risk of recurrent parasitaemia of
which 16% was due to recrudescence after treatment with
artemether-lumefantrine (AL) over a 42 day follow-up
period in a similar setting [35]. Since this current study
also reported a similar proportion of recurrence of parasi-
taemia in a hyper-endemic area, the high proportions
reported here as result of persistent antigenicity are possi-
ble and not a mere reflection of recrudescence or re-infec-
tion.
The study participants were drawn from a pool of all per-
sons suspected of having malaria, regardless of history,
clinical status, demographic characteristics or other fac-
tors that may affect sensitivity and specificity in a routine
health clinic. Inclusion of a large number of individuals
improved the precision of study estimates. Therefore, the
results obtained here reflect the performance of ICT in the
operational setting.
There were some limitations in the conduct of the study.
The evaluation was performed using microscopy as a gold
standard, fully aware of its limitations in detecting low
parasite densities [32]. To improve accuracy of readings,
two microscopists read all slides, blinded to each other's
reading. A third reading was done to determine a final
reading for all discordant field results. It is likely that
some participants were included in the cross-sectional
component of the study with circulating persistent anti-
Table 4: Proportion of children with persistent HRP2 antigenicity during follow-up in Soroti, Uganda
Duration(days) of follow-up Number that turned negative 
for antigen test
% Persistent antigen positive 
(n = 162)
% Persistent antigen positive (n 
= 224)*
30 1 0 0 1 0 0
7 5 97 98
14 14 88 84
21 41 63 60
28 35 41 35
35 38 18 14
42 14 9 7
49 10 3 2
56 4 1 0
63 1 0 0
* Inclusive of children with recurrent parasitaemia.Malaria Journal 2008, 7:221 http://www.malariajournal.com/content/7/1/221
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genemia. This may have led to a reduced specificity
because HRP2 antigens were detected for patients who
may have successfully eliminated their parasites. This
effect could have been overcome by using PCR to detect
very low parasite densities that may have been missed by
microscopy. However, this study was designed to evaluate
operational accuracy of ICT where such cases are impossi-
ble to distinguish from current infections when using
RDTs alone. It is assumed that there was no loss of quality
in the RDTs as result of temperature fluctuations during
transportation and storage. The storage temperature
ranged between 22–29°C during the study period, albeit
the single spike to 38°C recorded during transportation.
These readings are within the safe temperatures for HRP2-
based kits as reported in two previous studies [5,36].
The study team neither observed therapy nor assessed for
adherence to medication for the children during the lon-
gitudinal component. Poor adherence to treatment may
have led to recurrent parasitaemia as a result of treatment
failure.
RDTs devices are new technologies that resemble HIV test
kits formats previously used in this setting. During the fol-
low-up, a significant number of patients that had con-
sented to participate failed to honour all the scheduled
appointments. Only three patients formally withdrew
Proportion of children with persistent antigen in Soroti, Uganda Figure 2
Proportion of children with persistent antigen in Soroti, Uganda. Proportion of children with persistent antigen posi-
tive HRP2-RDT at clinic visits, stratified by day-zero parasite density at < 1,000/μl, 1,000–50,000/μl and > 50,000/μl. 224 chil-
dren were followed up with censoring for those with recurrent parasitaemias. The log rank test statistics for equality of 
survival distributions was 21.93 (p < 0.001).
 Malaria Journal 2008, 7:221 http://www.malariajournal.com/content/7/1/221
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consent mentioning that their families were suspicious
that these were actually HIV studies. It is likely that others
may have kept away from the study with similar misinfor-
mation. All patients' data collected during the evaluation
of persistent antigenicity was utilized to mitigate any
effect (bias) caused by loss to follow-up.
Conclusion
In conclusion, this study shows that ICT is an accurate test
for diagnosis of malaria in an operational setting where
microscopy is not available. It is a reliable test in detecting
P. falciparum infection in a highly endemic region of
Uganda. However, persistent antigenicity reduces the
accuracy of this and other HRP2-based RDTs. The low spe-
cificity continues to be of concern, especially in children
below five years of age, if they return with symptoms
within four weeks of previous antimalarial treatment. The
study highlights important practical issues that need con-
sideration when using RDTs for diagnosis. Good clinical
skills are essential to interpret test results given the persist-
ent antigenicity and specificity variation for age in
endemic areas. There is a need to explain to the end user
the best way to use the tools for diagnosis.
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